GHB Is a Bad Drug With a Good Side
WebMD News Archive
June 27, 2000 (Rockville, Md.) -- Consider a drug that's so powerful, it may even wipe out your memory of having taken it. GHB, or gamma-hydroxybutyrate, has a nasty reputation as a new drug used by partying young people. It also has a good side that most people don't hear about.
In lower doses, GHB is an experimental treatment for narcolepsy, a sleep disorder that can be deadly. GHB's also an approved therapy for alcoholism in Italy. Researcher Gian Luigi Gessa, MD, head of the neuroscience department at the University of Cagliari in Italy says GHB acts like methadone in heroin addicts, blocking the craving.
You can still purchase this intoxicating sedative over the Internet under many names like "Reneutrient" or "Blue Nitro." Barring that, the formula for this solvent is well known, and you could probably whip up a batch at home.
Perhaps, most chilling is that GHB is a colorless, tasteless liquid that's dropped into an unsuspecting victim's drink often as a prelude to rape. Even though President Clinton signed a measure into law in March making GHB illegal except for certain medical treatments, experts believe that more young people are using GHB, sometimes with disastrous consequences.
"It's so deadly, and it's been marketed by a lot of these companies as being either a growth hormone, or something to enhance sexual performance, or something to help you workout. So a lot of these users don't know what they're getting," Robert Mecir, special agent of the California Department of Justice, tells WebMD.
Mecir recently took part in a bust that netted 33, 55-gallon drums of GHB. The drug's street value is about $200 an ounce.
The Drug Enforcement Administration says that GHB has been linked to 66 deaths and some 5,700 overdoses, but, as disturbing as those numbers are, they may only be the beginning of the outbreak.
"With the demographics being under age 25, it's pretty frightening," Timothy Condon, PhD, associate director of the National Institute on Drug Abuse (NIDA), tells WebMD. Condon is one of about 50 participants attending an international meeting on GHB here Tuesday. The goal is to get a handle on this relatively new drug phenomenon before it gets out of hand.